Nature Communications (Sep 2021)
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
- Tanya E. Keenan,
- Jennifer L. Guerriero,
- Romualdo Barroso-Sousa,
- Tianyu Li,
- Tess O’Meara,
- Anita Giobbie-Hurder,
- Nabihah Tayob,
- Jiani Hu,
- Mariano Severgnini,
- Judith Agudo,
- Ines Vaz-Luis,
- Leilani Anderson,
- Victoria Attaya,
- Jihye Park,
- Jake Conway,
- Meng Xiao He,
- Brendan Reardon,
- Erin Shannon,
- Gerburg Wulf,
- Laura M. Spring,
- Rinath Jeselsohn,
- Ian Krop,
- Nancy U. Lin,
- Ann Partridge,
- Eric P. Winer,
- Elizabeth A. Mittendorf,
- David Liu,
- Eliezer M. Van Allen,
- Sara M. Tolaney
Affiliations
- Tanya E. Keenan
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jennifer L. Guerriero
- Breast Tumor Immunology Laboratory, Department of Cancer Biology, Dana-Farber Cancer Institute
- Romualdo Barroso-Sousa
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Tianyu Li
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
- Tess O’Meara
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Anita Giobbie-Hurder
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
- Nabihah Tayob
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
- Jiani Hu
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston
- Mariano Severgnini
- Center for Immuno-Oncology, Dana-Farber Cancer Institute
- Judith Agudo
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute
- Ines Vaz-Luis
- Medical Oncology Department, INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Institut Gustave Roussy
- Leilani Anderson
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Victoria Attaya
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jihye Park
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jake Conway
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Meng Xiao He
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Brendan Reardon
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Erin Shannon
- Broad Institute of Massachusetts Institute of Technology and Harvard
- Gerburg Wulf
- Hematology/Oncology, Beth Israel Deaconess Medical Center
- Laura M. Spring
- Breast Cancer, Cancer Center, Massachusetts General Hospital
- Rinath Jeselsohn
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ian Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Nancy U. Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ann Partridge
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eric P. Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Elizabeth A. Mittendorf
- Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center
- David Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sara M. Tolaney
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-021-25769-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze molecular correlates
